ERC Starting Grant · 2024
Understanding cancer metabolism at the individual patient level is central to making accurate early-stage diagnoses and providing effective patient-specific treatments. While some methods do exist to study intra-cell metabolomics and inter-cell metabolic flux alterations (e.g., PET, MRI), their scalability and sensitivity is limited, hindering reliable investigations long-term. LIFETIME aims to develop a single platform for "lifetime metabolomics", where the metabolic fingerprint of a disease is traced throughout patient onset in vivo, analysis ex vivo, and through to treatment. Technologically this involves rapid metabolomic profiling of the cancer model, using microfluidic…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.